A Phase 2 interventional study of Blinded (placebo) and Open Label (Avatrombopag tablets) in Idiopathic Thrombocytopenic Purpura, sponsored by Eisai Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-16.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 5 under way, 2 of them phase 3. avatrombopag · Purpura, Thrombocytopenic, Idiopathic.
Among the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 8th largest by enrollment, is one of 2 that started in 2007, is one of 4 in phase 2, and was the 2nd registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →5 of the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 2 countries. Recruiting first, the newest first:
Al-Mustansiriyah University · Sites in Iraq
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 6–18
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China
Ages 18+
Ostfold Hospital Trust
Ages 18+
By country, each count listing its studies:
avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 7 · Phase 4 2
First in 2007; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is close to the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 53 across the 16 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 16 have an industry lead sponsor. The 5 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 8 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and efficacy of AKR-501 (avatrombopag) administered in participants with chronic Idiopathic Thrombocytopenic Purpura (ITP) who were enrolled into and completed 28 days of study treatment in Protocol 501-CL-003 (NCT00441090).
Participants eligible to enroll into this rollover protocol will begin study treatment within 2-5 days of their Day 28 study termination visit in Protocol 501-CL-003 (NCT00441090). Participants who met the primary efficacy response criterion in Protocol 501-CL-003 will continue receiving the same study treatment to which they were assigned in the previous protocol in a double-blinded manner, these being one of the following 5 treatments:
Participants who did not meet the primary efficacy response criterion in Protocol 501-CL-003 who otherwise meet the eligibility criteria for this rollover protocol will be offered open label avatrombopag 10 mg daily.
This is a parallel group, rollover study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of the following drugs or treatments:
For more information regarding inclusion/exclusion criteria, please see record for AKR 501-CL-003 Protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Blinded (placebo)
Drug: Open Label (Avatrombopag tablets)
Drug: Blinded (Avatrombopoag tablets)
Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack) Duration - 6 months
Dose 10 mg Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack) Duration - 6 months
Also known as: AKR-501, E5501, YM477
Dose: 2.5, 5, 10, or 20 mg Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack) Duration - 6 months
Also known as: AKR-501, E5501, YM477
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
A TEAE was defined as 1) the AE started on or after the date of first dose of study drug up to and including 30 days after the last dose of study drug, or 2) the AE started before the first dose of study drug but worsened in severity on or after the date of first dose of study drug up to and including 3 days after the last dose of study drug. For participants having a tapering period of study drug, the last dose day is the last day of study drug during the tapering period. Related AEs included those whose relationship was categorized as possible or probably by the investigator. Dose interruption includes dose decreased, dose previously stopped, permanently stopped, or temporarily stopped. The safety population was divided into three subgroups based on the mean daily dose of active study drug taken; lower 1/3 (less than 8.85 mg avatrombopag), middle 1/3 (greater than or equal to 8.85 mg but less than 13.5 mg avatrombopag), and upper 1/3 (greater than or equal to 13.5 mg avatrombopag).
Time frame: Day 1 through Month 6 while receiving treatment and at Month 7 after discontinuation of treatment.
Incidence of Severe (Grade 3 or 4) TEAEs
A TEAE was defined as 1) the AE started on or after the date of first dose of study drug up to and including 30 days after the last dose of drug, or 2) the AE started before the first dose of study drug but worsened in severity on or after the date of first dose of study drug up to and including 3 days after the last dose of study drug. For participants having a tapering period of study drug, the last dose day is the last day of study drug during the tapering period. The safety population was divided into three subgroups based on the mean daily dose of active study drug taken; lower 1/3 (less than 8.85 mg avatrombopag), middle 1/3 (greater than or equal to 8.85 mg but less than 13.5 mg avatrombopag), and upper 1/3 (greater than or equal to 13.5 mg avatrombopag).
Time frame: Day 1 through Month 6 while receiving treatment and at Month 7 after discontinuation of treatment.
Incidence of Drug-Related TEAEs
Drug-related TEAEs included those whose relationship was categorized as possible or probably by the investigator. A TEAE was defined as 1) the AE started on or after the date of first dose of study drug up to and including 30 days after the last dose of drug, or 2) the AE started before the first dose of study drug but worsened in severity on or after the date of first dose of study drug up to and including 3 days after the last dose of study drug. For participants having a tapering period of study drug, the last dose day is the last day of study drug during the tapering period. The safety population was divided into three subgroups based on the mean daily dose of active study drug taken; lower 1/3 (less than 8.85 mg avatrombopag), middle 1/3 (greater than or equal to 8.85 mg but less than 13.5 mg avatrombopag), and upper 1/3 (greater than or equal to 13.5 mg avatrombopag).
Time frame: Day 1 through Month 6 while receiving treatment and at Month 7 after discontinuation of treatment.
Median Platelet Counts at Selected Analysis Timepoints
Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.
Time frame: Day 1, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4
Percentage of Participants Who Achieved a Platelet Count of 100,000/mm^3 or Higher by Response Status and Selected Study Visit
Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.
Time frame: Baseline (last PC before first dose of study drug in previous study), Weeks 2, 4, 8, 12, 16, 20, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4
Percentage of Participants Who Maintained a Platelet Count of 100,000/mm^3 or Higher by Response Status
Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.
Time frame: Baseline (last PC before first dose of study drug in previous study), Weeks 2, 4, 8, 12, 16, 20, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4
Percentage of Participants Who Achieved Response-Level Platelet Count by Selected Study Visit
Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.
Time frame: Baseline (last PC before first dose of study drug in previous study), Weeks 2, 4, 8, 12, 16, 20, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4
Percentage of Participants Who Maintained Response-Level Platelet Count
Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.
Time frame: Baseline (last PC before first dose of study drug in previous study), Weeks 2, 4, 8, 12, 16, 20, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4
Percentage of Participants Who Achieved a Durable, Transient, or Overall Platelet Response
Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.
Time frame: Baseline (last PC before first dose of study drug in previous study), Weeks 2, 4, 8, 12, 16, 20, 24, and Follow-up Weeks (after last dose of study drug in this study) 1, 2, 3, 4
Number of Participants With Changes in Concomitant Steroid Use
A participant who used steroids at study entry was considered to have permanently discontinued steroid use if they had no steroid use during the last 8 weeks of the study Treatment Period. A participant who used steroids at study entry was considered to have decreased concomitant steroid medication by at least 50% if they permanently discontinued steroids, or in no dose of steroid was higher than 50% of their baseline steroid dose during the last 8 weeks of the study Treatment Period.
Time frame: Day 1 through last 8 weeks of the Treatment Period
| Milestone | Lower 1/3 Avatromboopag Dose Group | Middle 1/3 Avatrombopag Dose Group | Upper 1/3 Avatrombopag Dose Group |
|---|---|---|---|
| Started | 12 | 26 | 15 |
| Completed | 10 | 15 | 10 |
| Not completed | 2 | 11 | 5 |
| Withdrew: Adverse event | 1 | 4 | 0 |
| Withdrew: Non-compliance with protocol | 0 | 1 | 0 |
| Withdrew: Platelet count increase >=500,000/mm3 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 |
| Withdrew: Physician decision | 0 | 4 | 2 |
| Withdrew: Other | 0 | 1 | 1 |
A TEAE was defined as 1) the AE started on or after the date of first dose of study drug up to and including 30 days after the last dose of study drug, or 2) the AE started before the first dose of study drug but worsened in severity on or after the date of first dose of study drug up to and including 3 days after the last dose of study drug. For participants having a tapering period of study drug, the last dose day is the last day of study drug during the tapering period. Related AEs included those whose relationship was categorized as possible or probably by the investigator. Dose interruption includes dose decreased, dose previously stopped, permanently stopped, or temporarily stopped. The safety population was divided into three subgroups based on the mean daily dose of active study drug taken; lower 1/3 (less than 8.85 mg avatrombopag), middle 1/3 (greater than or equal to 8.85 mg but less than 13.5 mg avatrombopag), and upper 1/3 (greater than or equal to 13.5 mg avatrombopag).
| Participants | Lower 1/3 Avatrombopag Dose Group | Middle 1/3 Avatrombopag Dose Group | Upper 1/3 Avatrombopag Dose Group |
|---|---|---|---|
| TEAEs | 12 | 24 | 14 |
| Severe (Grade 3-4) TEAEs | 4 | 7 | 6 |
| Treatment-related TEAEs | 5 | 15 | 7 |
| Serious TEAEs | 2 | 4 | 3 |
| Serious treatment-related TEAEs | 1 | 2 | 0 |
| Withdrawal of study drug due to TEAE | 2 | 4 | 0 |
| Dose interruption due to TEAE | 2 | 3 | 2 |
| Deaths | 0 | 0 | 0 |
A TEAE was defined as 1) the AE started on or after the date of first dose of study drug up to and including 30 days after the last dose of drug, or 2) the AE started before the first dose of study drug but worsened in severity on or after the date of first dose of study drug up to and including 3 days after the last dose of study drug. For participants having a tapering period of study drug, the last dose day is the last day of study drug during the tapering period. The safety population was divided into three subgroups based on the mean daily dose of active study drug taken; lower 1/3 (less than 8.85 mg avatrombopag), middle 1/3 (greater than or equal to 8.85 mg but less than 13.5 mg avatrombopag), and upper 1/3 (greater than or equal to 13.5 mg avatrombopag).
| Participants | Lower 1/3 Avatrombopag Dose Group | Middle 1/3 Avatrombopag Dose Group | Upper 1/3 Avatrombopag Dose Group |
|---|---|---|---|
| Thrombocytopenia | 1 | 2 | 4 |
| Splenomegaly | 0 | 0 | 1 |
| Haemorrhagic diathesis | 0 | 1 | 0 |
| Idiopathic thrombocytopenic purpura | 1 | 0 | 0 |
| Leukocytosis | 0 | 1 | 0 |
| Mitral valve incompetence | 0 | 0 | 1 |
| Diarrhoea | 0 | 0 | 1 |
| Vomiting | 0 | 0 | 1 |
| Fatigue | 2 | 0 | 0 |
| Oedema peripheral | 1 | 0 | 0 |
| Asthenia | 1 | 0 | 0 |
| Chest pain | 0 | 0 | 1 |
| Pyrexia | 0 | 0 | 1 |
| Platelet count increased | 2 | 1 | 0 |
| Platelet count decreased | 0 | 2 | 0 |
| Alanine aminotransferase increased | 0 | 0 | 1 |
| Aspartate aminotransferase increased | 0 | 0 | 1 |
| Hyperuricaemia | 1 | 0 | 0 |
| Back pain | 1 | 0 | 0 |
| Dizziness | 1 | 0 | 0 |
| Hypoaesthesia | 0 | 0 | 1 |
| Cerebrovascular accident | 0 | 0 | 1 |
| Haemorrhage intercranial | 0 | 1 | 0 |
| Epistaxis | 1 | 0 | 0 |
| Hypotension | 1 | 0 | 0 |
| Pelvic venous thrombosis | 0 | 1 | 0 |
Drug-related TEAEs included those whose relationship was categorized as possible or probably by the investigator. A TEAE was defined as 1) the AE started on or after the date of first dose of study drug up to and including 30 days after the last dose of drug, or 2) the AE started before the first dose of study drug but worsened in severity on or after the date of first dose of study drug up to and including 3 days after the last dose of study drug. For participants having a tapering period of study drug, the last dose day is the last day of study drug during the tapering period. The safety population was divided into three subgroups based on the mean daily dose of active study drug taken; lower 1/3 (less than 8.85 mg avatrombopag), middle 1/3 (greater than or equal to 8.85 mg but less than 13.5 mg avatrombopag), and upper 1/3 (greater than or equal to 13.5 mg avatrombopag).
| Participants | Lower 1/3 Avatrombopag Dose Group | Middle 1/3 Avatrombopag Dose Group | Upper 1/3 Avatrombopag Dose Group |
|---|---|---|---|
| Thrombocytopenia | 1 | 2 | 0 |
| Splenomegaly | 0 | 1 | 1 |
| Anaemia | 0 | 1 | 0 |
| Leukocytosis | 0 | 1 | 0 |
| Vision blurred | 0 | 1 | 0 |
| Visual disturbance | 0 | 1 | 0 |
| Nausea | 0 | 0 | 2 |
| Abdominal pain upper | 0 | 0 | 1 |
| Diarrhoea | 0 | 1 | 0 |
| Vomiting | 0 | 0 | 1 |
| Fatigue | 2 | 4 | 1 |
| Oedema peripheral | 0 | 1 | 0 |
| Platelet count increased | 2 | 2 | 0 |
| Platelet count decreased | 0 | 2 | 0 |
| Alanine aminotransferase increased | 0 | 1 | 0 |
| Hyperlipidaemia | 2 | 1 | 0 |
| Decreased appetite | 0 | 0 | 1 |
| Arthralgia | 0 | 1 | 1 |
| Back pain | 0 | 0 | 2 |
| Pain in extremity | 0 | 2 | 0 |
| Arthropathy | 0 | 1 | 0 |
| Muscular weakness | 0 | 0 | 1 |
| Headache | 2 | 1 | 1 |
| Dizziness | 1 | 1 | 1 |
| Hypoaesthesia | 0 | 0 | 1 |
| Mood swings | 1 | 0 | 0 |
| Haematuria | 0 | 1 | 0 |
| Menorrhagia | 1 | 0 | 0 |
| Dyspnoea | 1 | 1 | 0 |
| Epistaxis | 1 | 0 | 1 |
| Nasal congestion | 0 | 0 | 1 |
| Rash | 0 | 1 | 0 |
Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.
| Platelets x 1000/mm^3 | Responders | Nonresponders |
|---|---|---|
| Day 1 | 55.0 (7 to 316) | 23.5 (8 to 240) |
| Week 2 | 126.0 (39 to 855) | 54.5 (5 to 1207) |
| Week 4 | 113.0 (8 to 489) | 38.0 (6 to 383) |
| Week 6 | 104.0 (18 to 880) | 47.0 (10 to 731) |
| Week 8 | 137.0 (13 to 571) | 45.5 (3 to 263) |
| Week 10 | 85.5 (32 to 179) | 72.0 (9 to 702) |
| Week 12 | 88.0 (4 to 293) | 72.0 (2 to 557) |
| Week 14 | 84.0 (29 to 296) | 77.5 (9 to 368) |
| Week 16 | 143.0 (45 to 395) | 46.0 (3 to 273) |
| Week 18 | 119.0 (28 to 303) | 78.0 (17 to 382) |
| Week 20 | 92.0 (39 to 322) | 68.0 (18 to 481) |
| Week 22 | 109.0 (26 to 354) | 78.5 (14 to 502) |
| Week 24 | 154.0 (28 to 335) | 66.0 (19 to 368) |
| Follow-up Week 1 | 59.0 (8 to 495) | 40.0 (23 to 365) |
| Follow-up Week 2 | 25.0 (6 to 86) | 22.0 (8 to 426) |
| Follow-up Week 3 | 27.0 (3 to 380) | 36.0 (14 to 791) |
| Follow-up Week 4 | 35.0 (15 to 331) | 28.0 (1 to 881) |
Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.
| Percentage of participants | Responders | Nonresponders |
|---|---|---|
| Week 2 | 59.1 | 25.0 |
| Week 4 | 58.3 | 18.5 |
| Week 8 | 52.4 | 15.4 |
| Week 12 | 42.9 | 35.0 |
| Week 16 | 63.6 | 17.6 |
| Week 20 | 40.0 | 25.0 |
| Week 24 | 71.4 | 35.3 |
| Follow up Week 1 | 18.2 | 27.3 |
| Follow up Week 2 | 0 | 33.3 |
| Follow up Week 3 | 25.0 | 11.1 |
| Follow up Week 4 | 23.1 | 13.3 |
Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.
| Percentage of participants | Responders | Nonresponders |
|---|---|---|
| Percentage of Participants Who Maintained a Platelet Count of 100,000/mm^3 or Higher by Response Status | 32.0 | 0 |
Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.
| Percentage of participants | Responders | Nonresponders |
|---|---|---|
| Week 2 | 86.4 | 53.6 |
| Week 4 | 79.2 | 44.4 |
| Week 8 | 90.5 | 46.2 |
| Week 12 | 85.7 | 65.0 |
| Week 16 | 81.8 | 47.1 |
| Week 20 | 90.0 | 66.7 |
| Week 24 | 81.0 | 70.6 |
| Follow up Week 1 | 54.5 | 45.5 |
| Follow up Week 2 | 10.0 | 33.3 |
| Follow up Week 3 | 41.7 | 44.4 |
| Follow up Week 4 | 38.5 | 33.3 |
Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.
| Percentage of participants | Responders | Nonresponders |
|---|---|---|
| Percentage of Participants Who Maintained Response-Level Platelet Count | 56.0 | 0 |
Platelet count (PC) was measured from blood draws. Based on avatrombopag response in study 501-CL-003, participants were divided into two subgroups; 1) "Responders", participants who met the primary efficacy response; pretreatment PC was less than 30,000/mm\^3 and increased to greater than or equal to 50,000/mm\^3 after treatment with avatrombopag, and for participants on steroids, pretreatment PC was greater than or equal to 30,000/mm\^3 but less than 50,000/mm\^3 and increased to a PC greater than or equal to 20,000/mm\^3 above their pretreatment values and 2) "Nonresponders", participants who did not meet the primary efficacy response and those who were in the placebo arm. Open-label dose escalation of avatrombopag, as well as reductions in ITP-directed concomitant therapy (e.g. steroids) was allowed for all participants. During the periods of avatrombopag dose escalation and/or ITP-directed concomitant medication reduction, platelet sampling was done weekly.
| Percentage of participants | Responders | Nonresponders |
|---|---|---|
| Durable Platelet Response | 72.0 | 35.7 |
| Transient Platelet Response | 16.0 | 28.6 |
| Overall Response | 88.0 | 64.3 |
A participant who used steroids at study entry was considered to have permanently discontinued steroid use if they had no steroid use during the last 8 weeks of the study Treatment Period. A participant who used steroids at study entry was considered to have decreased concomitant steroid medication by at least 50% if they permanently discontinued steroids, or in no dose of steroid was higher than 50% of their baseline steroid dose during the last 8 weeks of the study Treatment Period.
| Number of participants | Responders | Nonresponders |
|---|---|---|
| Permanently Discontinued | 4 | 4 |
| Decreased by greater than or equal to 50% | 7 | 6 |
Collected over Approximately 7 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lower 1/3 Avatrombopag Dose Group | 0/12 (0%) | 2/12 (16.7%) | 12/12 (100%) |
| Middle 1/3 Avatrombopag Dose Group | 0/26 (0%) | 4/26 (15.4%) | 24/26 (92.3%) |
| Upper 1/3 Avatrombopag Dose Group | 0/15 (0%) | 3/15 (20%) | 14/15 (93.3%) |
| Event | Lower 1/3 Avatrombopag Dose Group | Middle 1/3 Avatrombopag Dose Group | Upper 1/3 Avatrombopag Dose Group |
|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 1/12 | 1/26 | 2/15 |
| Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders | 1/12 | 0/26 | 0/15 |
| Back painMusculoskeletal and connective tissue disorders | 1/12 | 0/26 | 0/15 |
| HypotensionVascular disorders | 1/12 | 0/26 | 0/15 |
| Mitral valve incompetenceCardiac disorders | 0/12 | 0/26 | 1/15 |
| VomitingGastrointestinal disorders | 0/12 | 1/26 | 1/15 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 0/26 | 1/15 |
| Chest painGeneral disorders | 0/12 | 0/26 | 1/15 |
| PyrexiaGeneral disorders | 0/12 | 0/26 | 1/15 |
| Cerebrovascular accidentNervous system disorders | 0/12 | 0/26 | 1/15 |
| Event | Lower 1/3 Avatrombopag Dose Group | Middle 1/3 Avatrombopag Dose Group | Upper 1/3 Avatrombopag Dose Group |
|---|---|---|---|
| FatigueGeneral disorders | 5/12 | 4/26 | 4/15 |
| HeadacheNervous system disorders | 2/12 | 7/26 | 3/15 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/12 | 3/26 | 4/15 |
| PetechiaeSkin and subcutaneous tissue disorders | 3/12 | 1/26 | 2/15 |
| ContusionInjury, poisoning and procedural complications | 3/12 | 3/26 | 3/15 |
| Gingival bleedingGastrointestinal disorders | 1/12 | 3/26 | 3/15 |
| NauseaGastrointestinal disorders | 0/12 | 1/26 | 3/15 |
| Oedema peripheralGeneral disorders | 1/12 | 2/26 | 3/15 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/12 | 4/26 | 3/15 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/12 | 1/26 | 3/15 |
Full analysis set (FAS) included all participants who completed 501-CL-003 and received study drug in 501-CL-004, except baseline values and ITP-directed medications taken during the 2-week period before the first dose of avatrombopag in 501-CL-004. Data was summarized using the observed case (OC) method.
| Age, Continuous(Years) | Lower 1/3 Avatrombopag Dose Group | Middle 1/3 Avatrombopag Dose Group | Upper 1/3 Avatrombopag Dose Group | Total |
|---|---|---|---|---|
| Geometric mean | 44.7 ± 21.09 | 52.5 ± 18.44 | 50.4 ± 15.65 | 50.1 ± 18.25 |
| Sex: Female, Male(Participants) | Lower 1/3 Avatrombopag Dose Group | Middle 1/3 Avatrombopag Dose Group | Upper 1/3 Avatrombopag Dose Group | Total |
|---|---|---|---|---|
| Female | 7 | 20 | 11 | 38 |
| Male | 5 | 6 | 4 | 15 |
The record gives a start of May 2007, a primary completion of Jun 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2018, 8 years 9 months after primary completion. A results delay was requested in May 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avatrombopag
Purpura, Thrombocytopenic, Idiopathic →